Advertisement

Tumor Biology

, Volume 37, Issue 4, pp 4393–4398 | Cite as

Mitotic arrest deficient-like 1 is correlated with poor prognosis in small-cell lung cancer after surgical resection

  • Dandan Li
  • Qingwei Meng
  • Huijuan Zhang
  • Ting Feng
  • Meiyan Liu
  • Li Cai
Original Article
  • 114 Downloads

Abstract

Mitotic arrest deficient-like 1 (MAD1L1) whose dysfunction is associated with chromosomal instability plays a pathogenic role in a few human cancers. However, the status of MAD1L1 expression in small-cell lung cancer (SCLC) remains unknown. Immunohistochemistry was used to determine the expression of MAD1L1 protein in 32 lymph node metastasis (LN-M) tissues and 88 primary SCLCs compared with 32 adjacent noncancerous tissues. The associations of MAD1L1 protein expression with the clinicopathologic features and clinical outcomes in patients with SCLC were analyzed. The ratio of MAD1L1 positive expression was higher in primary SCLC tissues (39.8 %) and LN-M tissues (46.9 %) compared with adjacent noncancerous tissues (9.4 %). MAD1L1 positive expression was associated with tumor-node-metastasis (TNM) stage (P = 0.003), International Association for the Study of Lung Cancer (IASLC) stage (P = 0.004), tumor size (P = 0.015), lymph node metastasis (P = 0.014), and recurrence (P < 0.001). Multivariate analysis suggested that MAD1L1 positive expression was an independent factor for overall survival (hazard ratio (HR) 2.002; 95 % confidence interval (CI) 1.065–3.763; P = 0.031) and recurrence-free survival (HR 2.263; 95 % CI 1.197–4.276; P = 0.012). To sum up, MAD1L1 positive expression may be associated with tumour progression and metastasis in SCLCs and may thus serve as a new biomarker for prognosis in these patients.

Keywords

Mitotic arrest deficient-like 1 Immunohistochemistry Prognosis Metastasis Recurrence 

Notes

Acknowledgments

This work is supported by a grant from the National Natural Science Foundation of China (No.30772540 and No.81172214).

Compliance with ethical standards

This study was approved by the Medical Ethics Committee of Harbin Medical University, and informed consent was obtained from the participating patients.

Conflicts of interest

None.

References

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.CrossRefPubMedGoogle Scholar
  2. 2.
    Devesa SS, Bray F, Vizcaino AP, Parkin DM. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer. 2005;117:294–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24:4539–44.CrossRefPubMedGoogle Scholar
  4. 4.
    Tartarone A, Lerose R, Ardito R, Troiani L, Tedesco B, Bozza G, et al. Long-term survival in small cell lung cancer: a case report and review of the literature. Future Oncol. 2014;10:523–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Pillai RN, Owonikoko TK. Small cell lung cancer: therapies and targets. Semin Oncol. 2014;41:133–42.CrossRefPubMedGoogle Scholar
  6. 6.
    Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clin Proc. 2008;83:355–67.CrossRefPubMedGoogle Scholar
  7. 7.
    Ma M, Wang M, Xu Y, Hu K, Liu H, Li L, et al. First-line chemotherapy and its survival analysis of 394 patients with extensive-stage small cell lung cancer in a single institute. Zhongguo Fei Ai Za Zhi. 2014;17:8–14.PubMedGoogle Scholar
  8. 8.
    Pleasance ED, Stephens PJ, O’Meara S, McBride DJ, Meynert A, Jones D, et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature. 2010;463:184–90.CrossRefPubMedGoogle Scholar
  9. 9.
    Tahir SK, Yang X, Anderson MG, Morgan-Lappe SE, Sarthy AV, Chen J, et al. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res. 2007;67:1176–83.CrossRefPubMedGoogle Scholar
  10. 10.
    Voortman J, Lee JH, Killian JK, Suuriniemi M, Wang Y, Lucchi M, et al. Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors. Proc Natl Acad Sci U S A. 2010;107:13040–5.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Jin DY, Spencer F, Jeang KT. Human T cell leukemia virus type 1 oncoprotein Tax targets the human mitotic checkpoint protein MAD1. Cell. 1998;93:81–91.CrossRefPubMedGoogle Scholar
  12. 12.
    Tsukasaki K, Miller CW, Greenspun E, Eshaghian S, Kawabata H, Fujimoto T, et al. Mutations in the mitotic check point gene, MAD1L1, in human cancers. Oncogene. 2001;20:3301–5.CrossRefPubMedGoogle Scholar
  13. 13.
    Yuan B, Xu Y, Woo JH, Wang Y, Bae YK, Yoon DS, et al. Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability. Clin Cancer Res. 2006;12:405–10.CrossRefPubMedGoogle Scholar
  14. 14.
    Han S, Park K, Kim HY, Lee MS, Kim HJ, Kim YD, et al. Clinical implication of altered expression of Mad1 protein in human breast carcinoma. Cancer. 2000;88:1623–32.CrossRefPubMedGoogle Scholar
  15. 15.
    Nomoto S, Haruki N, Takahashi T, Masuda A, Koshikawa T, Takahashi T, et al. Search for in vivo somatic mutations in the mitotic checkpoint gene, hMAD1, in human lung cancers. Oncogene. 1999;18:7180–3.CrossRefPubMedGoogle Scholar
  16. 16.
    Guo Y, Zhang X, Yang M, Miao X, Shi Y, Yao J, et al. Functional evaluation of missense variations in the human MAD1L1 and MAD2L1 genes and their impact on susceptibility to lung cancer. J Med Genet. 2010;47:616–22.CrossRefPubMedGoogle Scholar
  17. 17.
    Coe BP, Lee EH, Chi B, Girard L, Minna JD, Gazdar AF, et al. Gain of a region on 7p22.3, containing MAD1L1, is the most frequent event in small-cell lung cancer cell lines. Genes Chromosom Cancer. 2006;45:11–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Sun Q, Zhang X, Liu T, Liu X, Geng J, He X, et al. Increased expression of mitotic arrest deficient-like 1 (MAD1L1) is associated with poor prognosis and insensitive to taxol treatment in breast cancer. Breast Cancer Res Treat. 2013;140:323–30.CrossRefPubMedGoogle Scholar
  19. 19.
    Kienitz A, Vogel C, Morales I, Müller R, Bastians H. Partial downregulation of MAD1 causes spindle checkpoint inactivation and aneuploidy, but does not confer resistance towards taxol. Oncogene. 2005;24:4301–10.CrossRefPubMedGoogle Scholar
  20. 20.
    Tsukasaki K, Imaizumi Y, Tawara M, Fujimoto T, Fukushima T, Hata T, et al. Diversity of leukaemic cell morphology in ATL correlates with prognostic factors, aberrant immunophenotype and defective HTLV-1 genotype. Br J Haematol. 1999;105:369–75.CrossRefPubMedGoogle Scholar
  21. 21.
    Chun AC, Jin DY. Transcriptional regulation of mitotic checkpoint gene MAD1 by p53. J Biol Chem. 2003;278:37439–50.CrossRefPubMedGoogle Scholar
  22. 22.
    Iwanaga Y, Jeang KT. Expression of mitotic spindle checkpoint protein hsMAD1 correlates with cellular proliferation and is activated by a gain-of-function p53 mutant. Cancer Res. 2002;62:2618–24.PubMedGoogle Scholar
  23. 23.
    Nam CW, Park NH, Park BR, Shin JW, Jung SW, Na YW, et al. Mitotic checkpoint gene MAD1 in hepatocellular carcinoma is associated with tumor recurrence after surgical resection. J Surg Oncol. 2008;97:567–71.CrossRefPubMedGoogle Scholar
  24. 24.
    Zou L, Zhang P, Luo C, Tu Z. Mad1 suppresses bladder cancer cell proliferation by inhibiting human telomerase reverse transcriptase transcription and telomerase activity. Urology. 2006;67:1335–40.CrossRefPubMedGoogle Scholar
  25. 25.
    Osaki M, Inoue T, Yamaguchi S, Inaba A, Tokuyasu N, Jeang KT, et al. MAD1 (mitotic arrest deficiency 1) is a candidate for a tumor suppressor gene in human stomach. Virchows Arch. 2007;451:771–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Bhattacharjya S, Nath S, Ghose J, Maiti GP, Biswas N, Bandyopadhyay S, et al. miR-125b promotes cell death by targeting spindle assembly checkpoint gene MAD1 and modulating mitotic progression. Cell Death Differ. 2013;20:430–42.CrossRefPubMedGoogle Scholar
  27. 27.
    Rottmann S, Menkel AR, Bouchard C, Mertsching J, Loidl P, Kremmer E, et al. Mad1 function in cell proliferation and transcriptional repression is antagonized by cyclin E/CDK2. J Biol Chem. 2005;280:15489–92.CrossRefPubMedGoogle Scholar
  28. 28.
    Chen Y, Yeh PC, Huang JC, Yeh CC, Juang YL. The spindle checkpoint protein MAD1 regulates the expression of E-cadherin and prevents cell migration. Oncol Rep. 2012;27:487–91.PubMedGoogle Scholar
  29. 29.
    Rottmann S, Lüscher B. The Mad side of the Max network: antagonizing the function of Myc and more. Curr Top Microbiol Immunol. 2006;302:63–122.PubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Dandan Li
    • 1
  • Qingwei Meng
    • 2
  • Huijuan Zhang
    • 2
  • Ting Feng
    • 2
  • Meiyan Liu
    • 1
  • Li Cai
    • 2
  1. 1.Department of Pediatrics, The Affiliated Tumor HospitalHarbin Medical UniversityHarbinChina
  2. 2.The Fourth Department of Medical Oncology, The Affiliated Tumor HospitalHarbin Medical UniversityHarbinChina

Personalised recommendations